Crossmark

Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry

Crossref DOI link: https://doi.org/10.1186/s13052-018-0599-1

Published Online: 2019-01-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

De Bernardi, Bruno https://orcid.org/0000-0003-1755-8871
Di Cataldo, Andrea

Garaventa, Alberto

Massirio, Paolo

Viscardi, Elisabetta

Podda, Marta Giorgia

Castellano, Aurora

D’Angelo, Paolo

Tirtei, Elisa

Melchionda, Fraia

Vetrella, Simona

De Leonardis, Francesco

D’Ippolito, Carmelita

Tondo, Annalisa

Nonnis, Antonella

Erminio, Giovanni

Gigliotti, Anna Rita

Mazzocco, Katia

Haupt, Riccardo
License Information

Text and Data Mining valid from 2019-01-11
More Information

Article History

Received: 14 November 2018

Accepted: 19 December 2018

First Online: 11 January 2019

Ethics approval and consent to participate

: The RINB structure and protocol was approved by all the ethics committees of each participating center as a retrospective and prospective observational study. To be enrolled in the RINB, an informed consent form had to be signed by patients’ parents or guardians. For this reason, no specific further consent for this retrospective study needed to be sought. The RINB database is located at the secure Italian Inter-University Consortium CINECA headquarters in Italy, which is 9001:2015 and 27,001:2013 certified. It can be accessed only by authorized users.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.